Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Best Pract Res Clin Haematol. 2012 Oct 25;25(4):473–478. doi: 10.1016/j.beha.2012.10.010

Figure 1. Proteomic workflow identifying REG3α as the lead candidate GI GVHD biomarker.

Figure 1

Plasma pooled from 10 patients who never developed GVHD was compared to plasma pooled from 10 patients at the onset of GI GVHD. Of the 562 proteins initially identified, REG3α was chosen as the lead biomarker to validate because it was increased twofold in patients at the onset of GI GVHD, it is preferentially expressed in the GI tract and antibodies suitable for ELISA were commercially available.